US 12,227,479 B2
Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
Michael Ohlmeyer, New York, NY (US); and Dongming Cai, New York, NY (US)
Assigned to The United States Government as represented by the Department of Veterans Affairs, Washington, DC (US); and Icahn School of Medicine at Mount Sinai, New York, NY (US)
Filed by Icahn School of Medicine at Mount Sinai, New York, NY (US); and The United States Government as represented by the Department of Veterans Affairs, Washington, DC (US)
Filed on Oct. 10, 2022, as Appl. No. 17/963,036.
Application 17/963,036 is a continuation of application No. 16/763,962, granted, now 11,512,052, previously published as PCT/US2018/062020, filed on Nov. 20, 2018.
Claims priority of provisional application 62/588,983, filed on Nov. 21, 2017.
Prior Publication US 2023/0095139 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 211/90 (2006.01); A61P 25/28 (2006.01)
CPC C07D 211/90 (2013.01) [A61P 25/28 (2018.01)] 19 Claims
 
1. A method for treating cognitive impairment or traumatic brain injury in a patient, comprising administering to the patient a therapeutically effective amount of a compound having a structure represented by a formula:

OG Complex Work Unit Chemistry
wherein
R1 is selected from hydrogen, C1-C6 alkyl, and C3-C6 cycloalkyl; and
R2 is selected from hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, nitro, cyano, C1-C6 alkylthio, and C1-C6 haloalkylthio,
or a pharmaceutically acceptable salt thereof.